Glucagon-like peptide-1 receptor (GLP-1R) overexpression defines a distinct immunogenetic subset in primary and metastatic thyroid cancer: implications for GLP-1R agonist therapy - Quiz - MDSpire

Glucagon-like peptide-1 receptor (GLP-1R) overexpression defines a distinct immunogenetic subset in primary and metastatic thyroid cancer: implications for GLP-1R agonist therapy

  • By

  • Sophia Kennedy

  • Jerin Thomas

  • Stella D’Arcy

  • Ivie Odia

  • Dev Kamdar

  • Lucio Pereira

  • Danielle Scarola

  • Brett Miles

  • Douglas Frank

  • Charit Taneja

  • Nagashree Seetharamu

  • Rajarsi Mandal

  • May 28, 2026

  • 0 min

Share

Original Source(s)

Glucagon-like peptide-1 receptor (GLP-1R) overexpression defines a distinct immunogenetic subset in primary and metastatic thyroid cancer: implications for GLP-1R agonist therapy

  • by Sophia Kennedy, Jerin Thomas, Stella D’Arcy, Ivie Odia, Dev Kamdar, Lucio Pereira, Danielle Scarola, Brett Miles, Douglas Frank, Charit Taneja, Nagashree Seetharamu, Rajarsi Mandal

  • May 28, 2026

Related Content

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma

Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report